AHL Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

AHL Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.03M	Buy	4,317 +846	+24%	+$205K	0.02%	887
2017 Q3	$771K	Buy	3,471 +401	+13%	+$90.2K	0.01%	945
2017 Q2	$695K	Buy	3,070 +1,141	+59%	+$249K	0.01%	878
2017 Q1	$384K	Buy	+1,929	New	+$372K	0.01%	1030
2016 Q4	–	Sell	-4,107	Closed	-$673K	–	1048
2016 Q3	$673K	Buy	4,107 +1,093	+36%	+$166K	0.03%	712
2016 Q2	$431K	Buy	3,014 +1,088	+56%	+$155K	0.02%	639
2016 Q1	$263K	Sell	1,926 -16,755	-90%	-$2.2M	0.02%	688
2015 Q4	$2.59M	Buy	18,681 +15,638	+514%	+$2.17M	0.2%	189
2015 Q3	$409K	Sell	3,043 -31,582	-91%	-$4.55M	0.06%	450
2015 Q2	$5.21M	Sell	34,625 -5,952	-15%	-$852K	0.21%	159
2015 Q1	$5.49M	Buy	40,577 +18,935	+87%	+$2.35M	0.22%	138
2014 Q4	$2.61M	Buy	21,642 +18,288	+545%	+$2.1M	0.13%	322
2014 Q3	$380K	Buy	+3,354	New	+$397K	0.03%	545

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HCM

Hitchwood Capital Management New York $184M AUM 3.18% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AHL Partners's BIO Position: Q4 2017 in Review

AHL Partners increased its Bio-Rad Laboratories Class A (BIO) stake by 24% in Q4 2017, buying an estimated $205K and bringing the position to 4,317 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #887.

AHL Partners first reported a position in BIO in Q3 2014 and has held it in 13 quarters since. The position peaked at $5.49M in Q1 2015. 302 funds tracked by Wall St. Rank hold BIO as of Q4 2017.

AHL Partners held 4,317 shares of Bio-Rad Laboratories Class A worth $1.03M as of Q4 2017.
AHL Partners bought 846 Bio-Rad Laboratories Class A shares in Q4 2017, an estimated $205K.
Bio-Rad Laboratories Class A made up 0.02% of AHL Partners's portfolio in Q4 2017, its #887 holding.
AHL Partners first reported a position in Bio-Rad Laboratories Class A in Q3 2014 and has held it in 13 quarters since.
AHL Partners's Bio-Rad Laboratories Class A position peaked at $5.49M in Q1 2015.
302 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.